drugset
Drugs / allogeneic donor derived LMP specific cytotoxic T-lymphocyte
last change Dec 2017 re-read 3 minutes ago

allogeneic donor derived LMP specific cytotoxic T-lymphocyte

Cell therapy

Developed for
Hodgkins lymphoma
Investigated by
Baylor College of Medicine · Children's National Research Institute · City of Hope Medical Center · Johns Hopkins University · M.D. Anderson Cancer Center · New York Medical College
+3 more · Ohio State University · University of Michigan · University of Utah

Trials 1

today NCT01636388 · Ph 2
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01636388 Jan 2013 → Jun 2017 Hodgkins lymphoma New York Medical College Terminated No outcome recorded Stop: Business

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as allogeneic donor derived LMP specific cytotoxic T-lymphocyte ClinicalTrials.gov intervention name — accepted as the source's own label NCT01636388 ↗
Modality Cell therapy “Adoptive Cellular Immunotherapy” NCT01636388 ↗